WPD 401
Alternative Names: Interceptor - WPD Pharmaceuticals; Meteor - WPD Pharmaceuticals; WPD-401; WPD-402Latest Information Update: 11 Jun 2024
At a glance
- Originator WPD Pharmaceuticals
- Class Antineoplastics; Biological toxins; Recombinant fusion proteins
- Mechanism of Action EphA2 receptor antagonists; EphA3 receptor antagonists; Ephrin-B2 antagonists; Interleukin 13 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Breast cancer; Glioblastoma
Most Recent Events
- 09 May 2024 Discontinued - Preclinical for Breast cancer in Poland (IV) before May 2024 (WPD Pharmaceuticals Website, June 2024)
- 09 May 2024 Discontinued - Preclinical for Glioblastoma in Poland (unspecified route) before May 2024 (WPD Pharmaceuticals Website, June 2024)
- 31 Jan 2024 Early research in Glioblastoma in Poland (unspecified route) prior to January 2024